Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Jeffrey Gregg, MD, University of Nevada

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers

Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

Columns

Anatomic pathology selected abstracts

July 2025—Intraductal oncocytic papillary neoplasm of the pancreas is a recently recognized pancreatic tumor. The authors conducted a study to generate a comprehensive and quantitative summary of various aspects of intraductal oncocytic papillary neoplasms (IOPN). They searched the PubMed, Scopus, and Embase databases for studies reporting on pancreatic IOPN. Clinicopathologic, immunohistochemical, and molecular data were extracted from the studies and summarized. A comparative analysis of the molecular alterations of IOPN in juxtaposition with the typical molecular profile of conventional pancreatic ductal adenocarcinoma and intraductal papillary mucinous neoplasm from reference cohorts was subsequently conducted.

Molecular pathology selected abstracts

July 2025—Liver damage can result in a build up of scar tissue, or fibrosis, a hallmark of chronic liver disease (CLD). The latter has been attributed to a variety of risk factors, including viruses (primarily hepatitis B and C), obesity, and alcohol abuse. Furthermore, some patients have a genetic predisposition for the disease. Alpha-1 antitrypsin (A1AT) deficiency and hereditary hemochromatosis are two such inherited disorders that cause hepatocyte stress and damage. In A1AT deficiency, mutations in the SERPINA1 gene produce abnormal variants of the A1AT protein, which can accumulate in the liver and lead to hepatocyte damage. Mutations in the HFE gene are responsible for hereditary hemochromatosis.

Pathology informatics selected abstracts

July 2025—Computational pathology has largely focused on analyzing tissue slides and overlooked worthwhile information in gross images. Recognizing this, the authors introduced a novel deep learning model based on Swin Transformer architecture and called Swin Transformer-based Gross Features Detective Network (SGFD-network). They sought to summarize and classify the gross examination characteristics of ovarian epithelial tumors by analyzing images of gross specimens using this deep learning approach. The SGFD-network is especially useful for distinguishing borderline tumors with microinvasive components from frank carcinomas. This capability is crucial during frozen section analysis, in which limited sampling and time pressures often challenge diagnostic accuracy.

Q&A column

July 2025
Q. What is the best way to check machine precision? Is it acceptable to run precision replicates in quality control mode? Read answer.

Q. Several molecular diagnostic vendors circulate across U.S. hospitals and clinics to provide collection kits to physicians and request that those physicians refer tests outside the institution for what is sometimes described as clinical trials or research. The vendors operate using a pharmaceutical company model of selling proprietary testing directly to physicians and patients and bypassing the laboratory. It is a problem because laboratories are often expected to collect and submit samples and then enter complex reports into the electronic health record.

These companies are farming health systems for business and bypassing the accreditation process. When the testing is used not for research but instead for “the purpose of providing information for the diagnosis, prevention, or treatment of any disease or impairment of, or the assessment of the health of, human beings,” under U.S. law it is defined as laboratory testing (section 353 of the Public Health Service Act, 42 USC §263a), which is overseen by pathology laboratories and under pathology’s accreditation. Under this legal definition of laboratory testing, those outsourced tests are not research.

Can you comment on this practice from an accreditation perspective? Read answer.

Newsbytes

July 2025—PathAI and Chicago-based Northwestern Medicine have entered a multi-year venture in which Northwestern will implement PathAI’s AISight digital pathology image-management system. The two entities will also jointly undertake research initiatives and develop clinical innovation programs and artificial intelligence-powered diagnostic tools.

Put It on the Board

July 2025—The length of time to install digital pathology equipment, interface, implement, train, and go live in 10 large laboratories ranged from under one year to about 18 months, and the time spent prior to that—evaluating options, gaining budget approval, making decisions, and completing the contract and negotiation process—took eight months to a year for seven of the 10. For two others, the evaluation, decision-making, and contracting process took about 18 months, and for one it took five years, largely owing to pandemic-related delay.

Shorts on Standards: Regenstrief Institute and SNOMED International release 1st version of LOINC ontology

June 2025—Laboratories are subject to rigorous federal regulations such as continuous quality control, proficiency testing, and laboratory inspections to ensure high-quality test performance. However, few government mandates exist for the standardization of laboratory data. As a result, different laboratories have various local codes, names, reference ranges for normal and abnormal values, and formats of results and associated units for laboratory tests that might otherwise be similar or identical. While the lack of standardization is unlikely to impact the daily operations of individual laboratories, it does pose a significant barrier when results are compared or aggregated across institutions. It also poses challenges for secondary uses such as public health surveillance, outcomes analysis, research, and artificial intelligence/machine learning development.

From the President’s Desk

June 2025—June marks the American Medical Association’s annual meeting of its House of Delegates, and I’d like to use this month’s column to focus on why it’s so important for pathologists to work closely with the AMA. The short answer is this: We need to be at the table in the greater house of medicine. But isn’t it enough to be part of the CAP? After all, we are pathologists, and the CAP is far more focused on issues specific to our practice and our patients. And the CAP is constantly advocating for us at the federal and state levels of government, as well as with private payers.

Clinical pathology selected abstracts

June 2025—Semaglutide is a long-acting glucagon-like peptide-1 receptor agonist medication that has FDA approval for treating diabetes and obesity and that has shown exceptional efficacy. A rapid increase in use of this drug has been accompanied by reports of reduced alcohol use and cravings during semaglutide treatment. Alcohol use is a leading modifiable cause of morbidity and mortality and accounts for four to five percent of disease burden and 2.6 million deaths per year globally. Alcohol is also associated with increased risk of common diseases, including cardiovascular and liver disease and cancers. It is estimated that approximately 29 and 11 percent of U.S. adults meet lifetime and past-year criteria for alcohol use disorder (AUD), respectively.

Anatomic pathology selected abstracts

June 2025—Transbronchial cryobiopsies are increasingly used to diagnose interstitial lung disease, but published information on the features of specific manifestations of ILD in cryobiopsies is lacking. Therefore, the authors sought to provide pathologic guidelines for separating usual interstitial pneumonia (UIP) of idiopathic pulmonary fibrosis (IPF), fibrotic hypersensitivity pneumonitis (FHP), and connective tissue disease-associated interstitial lung disease (CTD-ILD) in cryobiopsies. They examined 120 cryobiopsies from patients with CTD-ILD established via multidisciplinary discussion and compared them with a prior series of 121 biopsies from patients with IPF or FHP also established via multidisciplinary discussion. A nonspecific interstitial pneumonia (NSIP) pattern alone was seen in 36 of 120 (30 percent) CTD-ILD, three of 83 (3.6 percent) FHP, and two of 38 (5.2 percent) IPF cases, statistically favoring a diagnosis of CTD-ILD.

MARKETPLACE

TRENDING